脑转移患者的死亡原因
Zane Schnurman1, Elad Mashiach1, Katherine E Link1
1Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
Neurosurgery
|May 31, 2023
概括
大多数脑转移患者的死亡是系统性疾病进展造成的,而不是中枢神经系统 (CNS) 疾病. 无法控制的系统性疾病和新的脑瘤,而不是局部瘤生长,驱动神经系统衰退和死亡.
科学领域:
- 神经瘤学神经瘤学
- 医学瘤学 医学瘤学
- 放射性外科手术是如何进行的
背景情况:
- 立体辐射手术 (SRS) 和向疗法改善了大脑转移的结果.
- 对于这些患者死亡率的主要驱动因素的了解有限.
- 描述死亡原因和内瘤动态对于指导管理和研究至关重要.
研究的目的:
- 确定脑转移患者死亡的主要原因.
- 为了评估死亡患者和幸存者之间内瘤动态的差异.
主要方法:
- 利用了NYUMets-Brain数据集,这是一个大型的,纵向的,现实世界的数据集.
- 审查了2012年至2021年期间接受SRS治疗的患者的电子健康记录.
- 使用多层模型对死亡原因进行分类并分析内瘤体积和数量变化.
主要成果:
- 73.1%的死亡是由于系统性疾病,10.3%是由于中枢神经系统疾病,16.6%是由于其他原因.
- 中枢神经系统死亡的主要原因是内瘤负担增加 (60%),神经学缺陷 (18%) 和发作 (11%).
- 与幸存者相比,在死亡的患者中,新的内瘤的发生率几乎是死亡患者的两倍 (P < .001).
结论:
- 系统性疾病进展是脑转移患者死亡的主要原因.
- 对于与中枢神经系统相关的死亡,由系统性疾病驱动的新瘤向大脑扩散似乎是主要因素.
- 管理策略应考虑系统性疾病控制对神经结果的影响.
相关概念视频
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
The Blood-brain Barrier
47.6K
Overview
47.6K
Electron Transport Chain: Complex I and II
14.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.6K


